Stabilis

Dexrazoxane hydrochloride



鍠喟搧鍚

Cardioxane	涓归害, 鍖堔墮鍒　鍘勤摐澶氩皵, 澧メタ鍋　濂ュ湴鍒　濮斿唴鍇炔媺, 宸磋夕, 寰峰浗, 鎰忏ぇ鍒　鏘哄埰, 娉曞浗, 娉㈠扂, 鐖卞皵鍏　绉橀曌, 鑽卞浗, 瑗跨彩鐧
Cyrdanax	寰峰浗, 娉曞浗
Dexrazoxane	鍘勤摐澶氩皵, 缇庡浗
Dexrazoxano	澧メタ鍋　绉橀曌
Razox	绉橀曌
Razoxane	鍋ヤ鸡姣旆簹
Rhianta	澧メタ鍋
Savene	涓归害, 鍖堔墮鍒　甯劳厞, 寰峰浗, 鎰忏ぇ鍒　鎸ｅ■, 姣斿埰鏃　娉曞浗, 娉㈠扂, 鐖卞皵鍏　鍖炩吁, 缃楅----灏间簹, 鑹　扂, 鑽卞浗, 鑽峰扂, 瑗跨彩鐧
Zinecard	鍔犳嬁澶　缇庡浗
Zucordex	澧メタ鍋

婧舵恫绋冲畾鎬

		10 mg/ml	25掳C		8			3611
		20 mg/ml	2-8掳C		4			3581
		20 mg/ml	25掳C		4			3581
		1 mg/ml	4掳C		24			381
		1 & 10 mg/ml	22掳C		6			381
		10 mg/ml	4掳C		6			381
PVC		1 mg/ml	25掳C		24			3611
PVC		1 mg/ml	4掳C		24			381
PVC		1 & 10 mg/ml	22掳C		6			381
PVC		3 mg/ml	25掳C		8			3611

PVC	RL	1 mg/ml	25掳C		24			3611
PVC	RL	3 mg/ml	25掳C		8			3611
PVC	RL	4 & 8 mg/ml	25掳C		8			2201
PE	RL	4 mg/ml	25掳C		4			2201
PE	RL	8 mg/ml	25掳C		8			2201
?		0,1 & 0,5 mg/ml	25掳C		24			1949
?		1 mg/ml	25掳C		12			1949
?	RL	3 & 4 mg/ml	25掳C	?	8			2224
?	RL	3 >> 10 mg/ml	25掳C		4			3581

褰卞摸绋冲畾鎬 x 殑鍥犵礌

					381
	10 mg / ml	4掳C			381

鍏煎　鎬

		Dexrazoxane hydrochloride : 5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Dexrazoxane hydrochloride : 5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Dexrazoxane hydrochloride		3611
		Dexrazoxane hydrochloride : 5 mg/ml Docetaxel : 0.9 mg/ml		1754
		Dexrazoxane hydrochloride		3611
		Dexrazoxane hydrochloride	RL	3581

鑾ㄨ嵂闔斿緞

	绉嶇被	鍑虹增鐗
381	鏂囝寮	Beijnen JH, Van Gijn R. Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids. J Parenter Sci Technol 1993 ; 47: 166-171.
1423	鏂囝寮	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1754	鏂囝寮	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1949	鏂囝寮	Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Rashko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, Doroshow JH. Phase I trial of 96 hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clinical Cancer Research 2001 ; 7: 1569-1576.
1953	鏂囝寮	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2201	鏂囝寮	Kaiser J.D, Vigneron J, Zenier H, May I, Demor? B. Chemical and physical stability of dexrazoxane, diluted with Ringer's lactate solution, in polyvinyl and polyethylene containers. EJHP Science 2007 ; 13, 3: 55-59.
2224	鏂囝寮	Romanazzi C, Sferra S, Campi A, Rabino B, Barbieri M, Castellani S, Sabbatini L, Scanavacca P. Dexrazoxane: Stabili膮 in soluzione. Bolletino SIFO 2007 ; 53: 178-180.
3581	瀹為獙瀹	Dexrazoxane (Cardioxane戶) - R茅sum茅 des caract茅ristiques du produit Clinigen Healthcare 2013
3611	鏂囝寮	Zhang, Y.-P, Myers, A.L., Trinh, V.A, Kawedia, J.D, Kramer, M.A, Benjamin, R.S, Tran, H.T. Physical and chemical stability of reconstituted and diluted dexrazoxane infusion solutions. J Oncol Pharm Practice 2014 ; 20, 1: 58-64.

瀛楀吁

	緇嗚優淇濇娟錌
	鍠喟搧鍚
	瀹瑰橠
	娴撳害
	淇濆瓨
	鑾熺墿浠胯＝钑
	寮曠敤鏂圂寮
	娉ㄥ皪鑾ㄦ按
	灝忔棣
	NaCl 0,9% 鎴　钁¤悇绯　5%
PVC	鑱氟隘涔欑儻
PE	鑱氫篁鐑
	钁¤悇绯　%
	褰卞搷绋冲畾鎬x殑鍥犵礌
	璇卞
	鍏煎　鎬
	婧跺墏
	NaCl 0,9%
	闈欒剞杈撳恫
	瀛楀吁

	娉ㄥ皪娑
	婧舵恫绋冲畾鎬
	鍒喟瓙
	娓十害
	绌十畾鎸佺簩鏘傞枔
	鏗涗浘鐨勦暩鐔
	鏨荤拑
	鍏
	閬垮厜
	鍏夛紡閬垮厜
RL	Ringer涔抽吁婧舵恫
?	涓嶪
?	鏃犻壒娈娴　姹
	澧烚姞
	娌爰穩
	鍒喟瓙
	鍏煎
	鏨ㄨ嵂閫斿緞
	寮曠敤鏂圂寮